Cite
APA Citation
Yu, E., Park, S. H., Huang, Y., Bennamoun, M., Xu, L., Kim, J., & Antonarakis, E. (n.d.). 345 Phase 3 study of combination pembrolizumab + olaparib therapy versus enzalutamide/abiraterone in metastatic castration-resistant prostate cancer (mCRPC) after progression on chemotherapy (KEYLYNK-010). Journal for immunotherapy of cancer, 8, A370. http://access.bl.uk/ark:/81055/vdc_100144719126.0x000004